CYTOSORBENTS CORPORATION Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYTOSORBENTS CORPORATION stock issued during period, value, conversion of convertible securities for the quarter ending 2013-12-31 was $0.00.
- CYTOSORBENTS CORPORATION stock issued during period, value, conversion of convertible securities for the quarter ending 2013-09-30 was $0.00.
- CYTOSORBENTS CORPORATION stock issued during period, value, conversion of convertible securities for fiscal 2014 was $24.27M, a 118975.39% increase from fiscal 2013.
- CYTOSORBENTS CORPORATION stock issued during period, value, conversion of convertible securities for fiscal 2013 was $20.39K, a 40.75% increase from fiscal 2012.
- CYTOSORBENTS CORPORATION stock issued during period, value, conversion of convertible securities for fiscal 2012 was $14.48K, a 92.27% decline from fiscal 2011.
- CYTOSORBENTS CORPORATION stock issued during period, value, conversion of convertible securities for fiscal 2011 was $187.46K, a 86.96% decline from fiscal 2010.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2014-12-31 | $24.27M 10-K · filed 2017-03-03 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $20.39K 10-K · filed 2015-03-31 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | |
| 2012-12-31 | $14.48K 10-K · filed 2014-03-31 | |
| 2011-12-31 | $187.46K 10-K · filed 2014-03-31 | |
| 2010-12-31 | $1.44M 10-K · filed 2014-03-31 | |
| 2009-12-31 | $681.56K 10-K · filed 2014-03-31 | |
| 2008-12-31 | $0.00 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |